Lilly Endowment Inc. has disclosed its ownership of 90,066,978 shares of Eli Lilly and Company, amounting to 9.6% of the pharmaceutical company's total shares. This significant stake was reported in a recent Schedule 13G/A filing made on October 19, 2026. The filing indicates that Lilly Endowment continues to maintain a strong position in Eli Lilly, reflecting its confidence in the company's future prospects.
As a private foundation organized under Indiana law, Lilly Endowment Inc. plays a crucial role in supporting various charitable initiatives. Its investment in Eli Lilly, a leader in the pharmaceutical preparations industry, underscores the endowment's strategy to align its financial interests with organizations that contribute to public health and well-being.
Background
Lilly Endowment Inc. is a not-for-profit corporation established in Indiana. It is primarily recognized for its philanthropic efforts and is classified under the Internal Revenue Code as a 501(c)(3) organization. The endowment's recent filings include a Schedule 13G/A on October 19, 2026, and a 13F-HR on the same date, indicating its active management of investments.
What the Filing Says
The Schedule 13G/A filing reveals that Lilly Endowment holds 90,066,978 shares of Eli Lilly, representing 9.6% of the company's common stock. The filing states, "The percentage of class represented is based on 941,357,065 shares of common stock outstanding as of August 3, 2026." This data reflects the endowment's significant influence over Eli Lilly's corporate governance.
Impact
This substantial ownership stake may affect various stakeholders, including shareholders, employees, and management at Eli Lilly. The endowment's investment reflects a long-term commitment to the company, potentially influencing strategic decisions and corporate policies.
What's Next
The filing does not say what happens next.